MedTrace Logo

Mifamurtide (L-MTP-PE) for High-Risk Osteosarcoma

NCT00631631 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 205

Last updated 2014-05-14

No results posted yet for this study

Summary

The purpose of this study was to collect information regarding the safety and tolerability of mifamurtide (liposomal muramyl tripeptide phosphatidyl ethanolamine; L-MTP-PE).

Conditions

Interventions

DRUG

Mifamurtide (L-MTP-PE)

Solution for intravenous infusion

Sponsors & Collaborators

  • Millennium Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Peter M. Anderson, MD, PhD · M.D. Anderson Cancer Center

Eligibility

Min Age
2 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2012-10-31
Completion
2012-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00631631 on ClinicalTrials.gov